Decision ruleHaematology

Smouldering myeloma progression risk (Mayo 2007 model)

Groups smouldering myeloma into three risk levels by marrow plasma cell percentage and serum monoclonal protein.

Updated 31 October 2026

When to use it

Patients with smouldering (asymptomatic) multiple myeloma at diagnosis, to estimate time to progression.

Warning

Model predates the 2014 IMWG criteria: with ≥ 60 % plasma cells, light-chain ratio ≥ 100 or > 1 focal MRI lesion the patient already has active myeloma. For current stratification prefer the 2/20/20 model.

What it needs

  • Bone marrow plasma cellsUnits: %
  • Serum monoclonal proteinUnits: g/dL, g/L

How to interpret it

Risk group
ResultInterpretation
≤ 0Not met: requires ≥ 10 % plasma cells or ≥ 3 g/dL monoclonal protein
1Group 1 (both factors): median time to progression ≈ 2 years
2Group 2 (plasma cells ≥ 10 %, protein < 3 g/dL): median ≈ 8 years
≥ 3Group 3 (protein ≥ 3 g/dL, plasma cells < 10 %): median ≈ 19 years

Practical tip

Overall progression risk is ≈ 10 % per year for the first 5 years and then falls (≈ 3 % per year for the next 5 and ≈ 1 % per year thereafter).

1 more practical tip in the app.

Reference

A support tool for healthcare professionals: it guides and does not replace clinical judgement.

Back to top